- Home
- BCTX vs IGC Comparison
BCTX vs IGC Comparison
Compare BCTX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCTX | IGC |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 28.5M |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BCTX | IGC |
|---|---|---|
| Price | $3.94 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $40.00 | $4.25 |
| AVG Volume (30 Days) | 180.1K | ★ 301.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | $380.95 | $15.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.61 | $0.24 |
| 52 Week High | $14.68 | $0.50 |
Technical Indicators
Market Signals| Indicator | BCTX | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 56.98 |
| Support Level | $3.60 | $0.29 |
| Resistance Level | $4.42 | $0.32 |
| Average True Range (ATR) | 0.26 | 0.02 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 50.31 | 58.00 |
Price Performance
Historical ComparisonAbout BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.